Teclistamab plus daratumumab and lenalidomide had a manageable safety profile in patients with transplant-ineligible, newly diagnosed multiple myeloma.
As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
At the conclusion of this year’s Myeloma Action Month, the International Myeloma Foundation (IMF) was truly grateful and overwhelmed by everyone’s support.